References
- Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991;324:1865–75.
- Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol 2006;62:509–11.
- Rosendaal FR. The Scylla and Charybdis of oral anticoagulant treatment. N Engl J Med 1996;335:587–9.
- Baglin TP, Keeling DM, Watson HG. British Committee for Standards. Guidelines on oral anticoagulation (warfarin): 3rd edition – 2005 update.Br J Haematol 2006;132: 277–85.
- Kim MJ, Huang SM, Meyer UA, Rahman A, Lesko LJ. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol 2009;49: 138–44.
- Wittkovsky AK. Drug interactions with oral anticoagulants. In: Colman RW, Clowes AW, Goldhaber SZ, Marder VJ, George JN, editors. Hemostasis and thrombosis, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. pp. 1699–709.
- Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008;112:1022–7.
- Bodin L, Verstuyft C, Tregouet DA, Robert A, Dubert L, Funck-Brentano C Jaillon P, Beaune P, Laurent-Puig P, Becquemont L, Loriot MA. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106:135–40.
- Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112:1013–21.
- Geisen C, Luxembourg B, Watzka M, Toennes SW, Sittinger K, Marinova M, von Ahsen N, Lindhoff-Last E, Seifried E, Oldenburg J. Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters. Eur J Clin Pharmacol 2011; 67:371–81.
- Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008;47:565–94.
- Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, LaRue S, Langlois N, Lazo-Langner A, Zou G, Roden DM, Stein CM, Rodger M, Carrier M, Forgie M, Wells PS, Kim RB. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood. 2011;118:3163–71.
- van Schie RM, de Boer A, Maitland-van der Zee AH. Implementation of pharmacogenetics in clinical practice is challenging. Pharmacogenomics 2011;12:1231–3.
- Kovac MK, Maslac AR, Rakicevic LB, Radojkovic DP. The c.-1639G> A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy. Blood Coagul Fibrinolysis 2010;21:558–63.
- Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH. The risk of over anticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004; 14:27–33.
- Gialeraki A, Markatos C, Grouzi E, Merkouri E, Travlou A, Politou M. Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity. Mol Biol Rep 2010;37:1693–7.
- Moridani M, Fu L, Selby R, Yun F, Sukovic T, Wong B, Cole DE. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Clin Biochem 2006;39:606–12.
- King CR, Porche-Sorbet RM, Gage BF, Ridker PM, Renaud Y, Phillips MS, Eby C. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose. Am J Clin Pathol 2008;129:876–83.
- Mattocks CJ, Morris MA, Matthijs G, Swinnen E, Corveleyn A, Dequeker E, Müller CR, Pratt V, Wallace A; EuroGentest Validation Group. A standardized framework for the validation and verification of clinical molecular genetic tests. Eur J Hum Genet 2010;18:1276–88.
- Howard R, Leathart JB, French DJ, Krishan E, Kohnke H, Wadelius M, van Schie R, Verhoef T, Maitland-van der Zee AH, Daly AK, Barallon R. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes. Clin Chim Acta 2011;412:2063–9.
- Kim S, Misra A. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng 2007;9: 289–320.
- Verhoef TI, Redekop WK, Buikema MM, Schalekamp T, Van Der Meer FJ, Le Cessie S. Long-term effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost 2012;10:606–14.